has become more popular among providers in recent years, is used to treat acute wounds from surgery and c-sections as well as several types of chronic wounds, including pressure and vascular ulcers.
“This addition results from a premier global health care services company seeking out InfuSystem and our unique expertise in providing clinic-to-home DME solutions,” said Richard Dilorio, the CEO of InfuSystem. “The core market to be targeted under the new agreement is U.S. home health care, which as a subset of the broader NPWT market has an estimated addressable market of $600 million per year.”
Dilorio noted that there will be an initial on-boarding period as the company prepares participating facilities to offer NPWT. That process should begin soon, but InfuSystem does not expect to see “meaningful revenue” from the therapy until the second half of 2020, he said.
In its announcement, InfuSystem noted that the American market for NPWT therapy is estimated to grow beyond $2 billion by 2024.
“We are excited to collaborate with a Top-10 health care services company on this new therapy and we look forward to a long and successful relationship,” Dilorio said.
